The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration

Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Int J Physiol Pathophysiol Pharmacol
Prif Awduron: Hammadi, Suleiman Al, Almarzooqi, Saeeda, Abdul-Kader, Hidaya Mohammed, Saraswathiamma, Dhanya, Souid, Abdul-Kader
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: e-Century Publishing Corporation 2015
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/
https://ncbi.nlm.nih.gov/pubmed/26823960
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg